At close: December 19 at 8:16:45 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
303.0000
Operating Expense
14,653.0000
13,321.0000
19,712.0000
12,426.0000
9,887.0000
Operating Income
-14,653.0000
-13,321.0000
-19,712.0000
-12,426.0000
-9,584.0000
Net Non Operating Interest Income Expense
-3,400.0000
5.0000
-564.0000
-913.0000
-1,057.0000
Other Income Expense
--
--
1.0000
-60.0000
2,400.0000
Pretax Income
-12,885.0000
-13,316.0000
-20,275.0000
-13,399.0000
-8,241.0000
Net Income Common Stockholders
-12,885.0000
-13,316.0000
-20,275.0000
-13,399.0000
-8,241.0000
Diluted NI Available to Com Stockholders
-12,885.0000
-13,316.0000
-20,275.0000
-13,399.0000
-8,241.0000
Basic EPS
-2.16
-4.24
-11.55
-16.65
-27.90
Diluted EPS
-2.37
-4.24
-11.55
-16.65
-27.90
Basic Average Shares
5,798.8430
3,140.9250
1,750.3500
805.9450
295.1890
Diluted Average Shares
7,464.0040
3,140.9250
1,750.3500
805.9450
295.1890
Total Operating Income as Reported
-14,653.0000
-13,321.0000
-19,712.0000
-12,492.0000
-9,584.0000
Total Expenses
14,653.0000
13,321.0000
19,712.0000
12,426.0000
9,887.0000
Net Income from Continuing & Discontinued Operation
-12,885.0000
-13,316.0000
-20,275.0000
-13,399.0000
-8,241.0000
Normalized Income
-18,053.0000
-13,316.0000
-20,275.0000
-13,339.0000
-10,641.0000
Interest Income
329.0000
400.0000
147.0000
19.0000
50.0000
Interest Expense
3,729.0000
395.0000
711.0000
932.0000
1,107.0000
Net Interest Income
-3,400.0000
5.0000
-564.0000
-913.0000
-1,057.0000
EBIT
-9,156.0000
-12,921.0000
-19,564.0000
-12,467.0000
-7,134.0000
EBITDA
-8,471.0000
-12,293.0000
-18,945.0000
-12,072.0000
-6,768.0000
Reconciled Depreciation
685.0000
628.0000
619.0000
395.0000
366.0000
Net Income from Continuing Operation Net Minority Interest
-12,885.0000
-13,316.0000
-20,275.0000
-13,399.0000
-8,241.0000
Total Unusual Items Excluding Goodwill
5,168.0000
--
1.0000
-60.0000
2,400.0000
Total Unusual Items
5,168.0000
--
1.0000
-60.0000
2,400.0000
Normalized EBITDA
-13,639.0000
-12,293.0000
-18,945.0000
-12,012.0000
-9,168.0000
12/31/2020 - 12/28/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
UKJ2.DU Opthea Ltd. R
3.0200
+3.42%
OEZ.DU Avecho Biotechnology Ltd
0.0005
-50.00%
W2J.MU CARISMA Therapeutics Inc
0.4342
0.00%
CLA.MU Akari Therapeutics PLC R
0.9300
0.00%
ECQ.F
PQ6.F Starpharma Holdings Limited
0.0535
+1.90%
G1G.SG Zelira Therapeutics Ltd
0.3580
+1.70%
MDBBF Medlab Clinical Limited
15.75
0.00%
E4NA.SG Arovella Therapeutics Ltd
0.0970
0.00%
ETXPF e-therapeutics plc
0.1300
0.00%